JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment
Ghosh, Saptarshi; Rao, Pamidimukkala Brahmananda; Kumar, P Ravindra; Manam, Surendra;
  PDF(new window)
 Abstract
Background: Concurrent chemoradiation with three weekly high dose cisplatin is the non-surgical standard of care for the treatment of locally advanced head and neck cancers. Although this treatment regime is efficacious, it has high acute toxicity, which leads not only to increased treatment cost, but also to increased overall treatment time. Hence, the current study was undertaken to evaluate the acute toxicity and tumor response in head and neck cancer patients treated with concurrent chemoradiation using weekly cisplatin, which has been our institutional practice. Materials and Methods: This single institution retrospective study included data for 287 head and neck cancer patients treated with concurrent chemoradiation from 2012 to 2014. Results: The mean age of the patients was 48.8 years. The most common site of involvement was oral cavity. Most of the study patients presented with advanced stage disease. The mean overall treatment time was 56.9 days. Some 67.2% had overall complete response to treatment as documented till 90 days from the start of treatment. According to the Radiation Therapy Oncology Group (RTOG) acute radiation morbidity scoring criteria, mucositis was seen in 95.1% of the patients. Dermatitis and emesis were observed in 81.9% and 98.6%, respectively. Regarding haematological toxicity, 48.8% and 29.6% suffered from anaemia and leukopenia, respectively, during treatment. Acute kidney injury was assessed using the Common Terminology Criteria for Adverse Events (CTCAE), and was found in 18.8% of the patients. Conclusions: Concurrent chemoradiotherapy with weekly cisplatin is an effective treatment regime for head and neck cancers with reasonable toxicity which can be used in developing countries, where cost of treatment is so important.
 Keywords
Cobcurrent chemoradiation;RTOG;CTCAE;developing countries;efficacy;
 Language
English
 Cited by
1.
Tolerance of Chemoradiation in Advanced Head and Neck Cancers: Comparison Between Inpatients and Outpatients, Indian Journal of Otolaryngology and Head & Neck Surgery, 2017, 0973-7707  crossref(new windwow)
 References
1.
Adelstein DJ, Li Y, Adams GL, et al (2003). An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemo-radiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol, 21, 92-8. crossref(new window)

2.
Baykara M, Buyukberber S, Ozturk B, et al (2013). Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers. Asian Pac J Cancer Prev, 14, 2557-61. crossref(new window)

3.
Brizel DM, Esclamado R (2006). Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol, 24, 2612-17. crossref(new window)

4.
Browman GP, Hodson DI, Mackenzie RG, et al (2001). Cancer care ontario practice guideline initiative head and neck cancer disease site group: choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck, 23, 579-89. crossref(new window)

5.
Chaturvedi P (2009). Head and neck surgery. J Can Res Ther, 5, 143.

6.
Cox JD, Stetz J, Pajak TF (1995). Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys, 31, 1341-6. crossref(new window)

7.
Dimri K, Pandey AK, Trehan R, et al (2013). Conventional radiotherapy with concurrent weekly cisplatin in locally advanced head and neck cancers of squamous cell origin- a single institution experience. Asian Pac J Cancer Prev, 14, 6883-88. crossref(new window)

8.
Fan KY, Gogineni H, Zaboli D, et al (2012). Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma. Ann Surg Oncol, 19, 1980-7. crossref(new window)

9.
Forastiere AA, Goepfert H, Maor M, et al (2003). Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med, 349, 2091-98. crossref(new window)

10.
Geeta SN, Padmanabhan TK, Samuel J, et al (2006). Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers. J Cancer Res Ther, 2, 100-4. crossref(new window)

11.
Gupta T, Agarwal JP, Ghosh-Laskar S, et al (2009). Radical radiotherapy with concurrent weekly cisplatin in locoregionally advanced squamous cell carcinoma of the head and neck: a single-institution experience. Head Neck Oncol, 1, 17. crossref(new window)

12.
Lasrado S, Moras K, Pinto GJO, et al (2014). Role of concomitant chemoradiation in locally advanced head and neck cancers. Asian Pac J Cancer Prev, 15, 4147-52. crossref(new window)

13.
Marcu L, van Doorn T, Olver I (2003). Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer. Acta Oncol, 42, 315-25. crossref(new window)

14.
Mishra A, Meherotra R (2014). Head and neck cancer: Global burden and regional trends in India. Asian Pac J Cancer Prev, 15, 537-50. crossref(new window)

15.
Pandey KC, Revannasiddaiah S, Pant NK, et al (2014). Stagewise presentation of non-metastatic head and neck cancer: an analysis of patients from the Kumaon hills of India. Asian Pac J Cancer Prev, 15, 4957-61. crossref(new window)

16.
Pignon JP, Maitre AL, Bourhis J (2007). Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): An update. Int J Radiat Oncol Biol Phys, 69, 112-4.

17.
Pignon JP, Bourhis J, Domenge C, et al (2000). Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet, 355, 949-55. crossref(new window)

18.
Pignon JP, Baujat B, Bourhis J (2005). Individual patient data meta-analysesin head and neck carcinoma: What have we learnt? Cancer Radiother, 9, 31-6. crossref(new window)

19.
Pignon JP, le Maitre A, Maillard E, et al (2009). MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol, 92, 4-14. crossref(new window)

20.
Pruegsanusak K, Peeravut S, Leelamanit V, et al (2012). Survival and prognostic factors of different sites of head and neck cancer: an analysis from Thailand. Asian Pac J Cancer Prev, 13, 885-90. crossref(new window)